Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects

Citation
Kwm. Bloemenkamp et al., Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects, ARCH IN MED, 160(1), 2000, pp. 49-52
Citations number
30
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
ARCHIVES OF INTERNAL MEDICINE
ISSN journal
00039926 → ACNP
Volume
160
Issue
1
Year of publication
2000
Pages
49 - 52
Database
ISI
SICI code
0003-9926(20000110)160:1<49:HROVTD>2.0.ZU;2-F
Abstract
Background: Results of recent studies show that the risk for venous thrombo sis is highest during initial oral contraceptive use. This suggests a subgr oup of females who are at immediate risk of thrombosis when exposed to oral contraceptives. Objective: To determine whether women with inherited clotting defects who u se oral contraceptives develop venous thrombosis at an earlier stage than d o those without inherited clotting defects. Methods: Analysis of the data from the Leiden Thrombophilia Study, a popula tion-based case-control study with data on duration of oral contraceptive u se and recently detected genetic coagulation disorders. Patients had a firs t episode of objectively proven deep vein thrombosis. Patients and controls were considered thrombophilic when they had protein C deficiency, protein S deficiency, antithrombin deficiency, factor V leiden mutation, or prothro mbin 20210 A mutation. Results: Risk of developing deep vein thrombosis was greatest in the first 6 months and the first year of oral contraceptive use. Compared with prolon ged use, the risk of developing deep vein thrombosis was 3-fold higher in t he first 6 months of use (95% confidence interval [CI], 0.6-14.8) and 2-fol d higher in the first year of use (95% CI, 0.6-6.1). Patients who developed venous thrombosis in the early periods of use were more often thrombophili c. Among women with thrombophilia, the risk of developing deep vein thrombo sis during the first 6 months of oral contraceptive use (compared with prol onged use) was increased 19-fold (95% CI, 1.9-175.7), and in the first year of use, it was increased Ii-fold (95% CI, 2.1-57.3). Conclusions: Women with inherited clotting defects who use oral contracepti ves develop venous thrombosis not only more often but also sooner than do t hose without inherited clotting defects. Venous thrombosis in the first per iod of oral contraceptive use might indicate the presence of an inherited c lotting defect.